Evidence map›Paper›PMID 42486391›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2026

Cytomegalovirus infection after lung transplant: Incidence, risk factors, and management in a multicenter cohort.

Laurie D Snyder, Jeremy M Weber, Robin Avery, Megan L Neely, Mark A Robien, Joanna Schaenman, Wayne M Tsuang, S Samuel Weigt, Deepali Kumar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Laurie D SnyderDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, USA; Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA. Electronic address: Laurie.snyder@duke.edu.
Jeremy M WeberDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
Robin AveryDepartment of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Megan L NeelyDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.
Mark A RobienTransplantation Branch, Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID), Rockville, Maryland, USA.
Joanna SchaenmanDepartment of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA.
Wayne M TsuangDepartment of Pulmonary and Critical Care Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
S Samuel WeigtDepartment of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA.
Deepali KumarAjmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.

Funding

The Lung Transplant Clinical Trials Network (LT-CTN)U01AI113315 · NIAID · DUKE UNIVERSITY · PI PALMER, SCOTT M · 2014 to 2018
$12.9M
NIAID NIH HHS U01 AI113315
6 · The paper itself

Abstract

Cytomegalovirus (CMV) infection after lung transplant is associated with chronic rejection, but risk factors besides serology are not well-defined. Utilizing a multicenter, prospective cohort, CMV infection risk factors during and after prophylaxis were analyzed with an extended Cox model, occurring either after completion of primary prophylaxis or for a breakthrough CMV episode, while on prophylaxis. The overall cohort included 785 lung transplant recipients, of which 221 developed at least 1 CMV episode. Of the 362 recipients eligible for the off-prophylaxis analysis, 124 had a CMV episode a median of 57 days postprophylaxis. In adjusted models of off-prophylaxis, an increased risk of CMV was noted for donor CMV immunoglobulin G seropositive (D+)/recipient CMV immunoglobulin G seronegative (R-) serostatus, shorter duration of previous CMV prophylaxis, and augmented immunosuppression with either high-dose steroids or T cell-targeted therapy. In the 586 recipients eligible for the breakthrough CMV analysis, 71 had a CMV episode, and in adjusted models while on primary prophylaxis, CMV D+/R- serostatus was the only significant risk factor. Although CMV D+/R- serostatus remains an important risk factor for CMV, additional risk factors include prophylaxis duration and augmented immunosuppression, which should be considered in CMV prevention after lung transplant.

Indexed as

cytomegaloviruslung transplantviral prophylaxis

Identifiers

PMID42486391
PMCPMC13591396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.